MedTrace Logo

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

NCT01028963 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2025-03-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B in subjects with Type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Placebo

Placebo capsules once daily

DRUG

pioglitazone

pioglitazone 30 mg tablet once daily

DRUG

CCX140-B

CCX140-B capsules once daily (Group C)

DRUG

CCX140-B

CCX140-B capsules once daily (Group D)

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-10-31
Completion
2010-11-30

Countries

  • Australia
  • Czechia
  • Germany
  • Hungary
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01028963 on ClinicalTrials.gov